TNF-Derived Polypeptide Inhibits Necroptosis via Antibody Competition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammatory diseases, such as rheumatoid arthritis and sepsis, are limited by the inability to effectively modulate or reverse cellular necrosis, leading to significant side effects and incomplete resolution of inflammation, as traditional TNF-blocking antibodies are not effective in addressing necroptosis mechanisms.

Innovation Solution

A polypeptide derived from wild-type TNFα, comprising 10-200 amino acid residues with the sequence QLVVPSE, which competes with TNF for binding to cell necrosis-promoting antibodies without interacting with TNFR1, thereby inhibiting cell necrosis and treating inflammatory diseases like rheumatoid arthritis, Crohn's disease, and sepsis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional TNF-blocking antibodies are used to treat inflammatory diseases, then TNF function is blocked, but side effects such as infections and tumors occur due to complete blockage of TNF functions

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects (infections and tumors)

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the TNF function into two distinct pathways: the pro-inflammatory necroptosis pathway (targeted by the polypeptide) and the protective NF-κB signaling pathway (preserved). By designing a polypeptide that specifically binds to necroptosis-promoting antibodies rather than blocking all TNF functions, the treatment selectively inhibits harmful necroptosis while maintaining protective TNF activities, thus resolving the contradiction between treatment effectiveness and side effects

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The polypeptide acts as an intermediary substance that binds to necroptosis-promoting antibodies, preventing them from triggering necroptosis. This intermediary mechanism allows selective neutralization of harmful autoantibodies without blocking TNF's protective functions, thereby achieving effective inflammation control while avoiding the severe side effects associated with complete TNF blockade

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-generated harmful factors

If TNF-blocking antibodies completely block TNF functions, then inflammatory responses are suppressed, but life-threatening side effects occur

Engineering Contradiction:

Improveinflammatory responsesVSAvoidlife-threatening side effects

Core Design Contradiction:

Object-generated harmful factorsVSObject-affected harmful factors

Solution Approach 1:

Instead of blocking TNF functions directly (the conventional approach), the invention inverts the strategy by targeting the harmful antibodies that promote necroptosis. The polypeptide binds to necroptosis-promoting antibodies, inverting the conventional therapeutic approach from 'blocking the cytokine' to 'neutralizing the harmful antibodies,' thereby suppressing inflammation while preserving TNF's protective functions and avoiding life-threatening side effects

Inventive Principle:

Principle #13The other way round (Inversion)

3Reliability

If anti-TNF biologics are used to treat inflammatory diseases, then clinical effectiveness is achieved, but the mechanism of cell and tissue destruction remains unknown and incomplete treatment occurs

Engineering Contradiction:

Improveclinical effectivenessVSAvoidmechanism understanding

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The invention extracts and specifically targets the necroptosis-promoting antibody component from the complex TNF signaling system. By isolating and neutralizing this specific harmful element rather than broadly blocking TNF functions, the treatment addresses the previously unknown mechanism of cell and tissue destruction in inflammatory diseases, providing both clinical effectiveness and mechanistic clarity

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The polypeptide effectively inhibits cell necrosis and reduces inflammatory responses in patients with inflammatory diseases, avoiding the side effects associated with traditional TNF-blocking therapies by targeting necroptosis-inducing autoantibodies, thus providing a safer and more effective treatment option.

Implementation Method 1

competes with TNF for binding to a cell necrosis-promoting antibody

Methodology Applied

Scientific EffectCompetitive binding:

Data Source

PatentEP3381934B1Protein for neutralizing programmed necrocytosis promotion antibody, and application of protein

Publication Date: 2023.05.31 SHANGHAI JW INFLINHIX CO LTD

Figure 1~2
Figure 3
Figure 4

AI summary

Provided is polypeptide which derives from wild type TNF a and inhibits necrocytosis. The polypeptide contains 10-200 amino acid residues and a sequence QLWPSE. Also provided is a pharmaceutical composition containing polypeptide. The polypeptide and the pharmaceutical composition containing the polypeptide are capable of inhibiting necrocytosis, thereby being used for treating inflammatory diseases.